Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency
L Guantay, C Garro, S Siri, MF Pansa… - Drug Resistance …, 2023 - Elsevier
BRCA2 is a well-established cancer driver in several human malignancies. While the
remarkable success of PARP inhibitors proved the clinical potential of targeting BRCA …
remarkable success of PARP inhibitors proved the clinical potential of targeting BRCA …